# Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients

> **NCT05306249** · PHASE2 · COMPLETED · sponsor: **Centre Hospitalier Régional d'Orléans** · enrollment: 80 (actual)

## Conditions studied

- HIV Seropositivity

## Interventions

- **DRUG:** CBD LGP 50
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05306249
- **Lead sponsor:** Centre Hospitalier Régional d'Orléans
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-16
- **Primary completion:** 2023-02-08
- **Final completion:** 2023-02-08
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2023-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05306249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05306249, "Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05306249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*